Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 457

1.

External Validation and Recalculation of the CODEX Index in COPD Patients. A 3CIAplus Cohort Study.

Almagro P, Martínez-Camblor P, Miravitlles M, Rodríguez-Carballeira M, Navarro A, Lamprecht B, Ramirez-Garcia Luna AS, Kaiser B, Alfageme I, Casanova C, Esteban C, Soler-Cataluña JJ, de-Torres JP, Celli BR, Marin JM, Ter Riet G, Sobradillo P, Lange P, Garcia-Aymerich J, Anto JM, Turner AM, Han MK, Langhammer A, Sternberg A, Leivseth L, Bakke P, Johannessen A, Oga T, Cosío B, Ancochea J, Echazarreta A, Roche N, Burgel PR, Sin DD, Puhan MA, Soriano JB; 3CIA collaboration.

COPD. 2019 Mar 14:1-10. doi: 10.1080/15412555.2018.1484440. [Epub ahead of print]

PMID:
30870059
2.

Diagnosis and management of α1-antitrypsin deficiency in Europe: an expert survey.

Horváth I, Canotilho M, Chlumský J, Chorostowska-Wynimko J, Corda L, Derom E, Ficker JH, Kneussl M, Miravitlles M, Sucena M, Thabut G, Turner AM, van 't Wout E, McElvaney NG.

ERJ Open Res. 2019 Mar 11;5(1). pii: 00171-2018. doi: 10.1183/23120541.00171-2018. eCollection 2019 Feb.

3.

Practical Guide to the Identification and Diagnosis of Asthma-COPD Overlap (ACO).

Nuñez A, Sarasate M, Loeb E, Esquinas C, Miravitlles M, Barrecheguren M.

COPD. 2019 Feb 21:1-7. doi: 10.1080/15412555.2019.1575802. [Epub ahead of print]

PMID:
30789039
4.

The European Alpha-1 Research Collaboration (EARCO): a new ERS Clinical Research Collaboration to promote research in alpha-1 antitrypsin deficiency.

Miravitlles M, Chorostowska-Wynimko J, Ferrarotti I, McElvaney NG, O'Hara K, Stolk J, Stockley RA, Turner A, Wilkens M, Greulich T; EARCO Clinical Research Collaboration; Members of the EARCO Clinical Research Collaboration.

Eur Respir J. 2019 Feb 14;53(2). pii: 1900138. doi: 10.1183/13993003.00138-2019. Print 2019 Feb. No abstract available.

PMID:
30765486
5.

Correction: Testing for alpha-1 antitrypsin in COPD in outpatient respiratory clinics in Spain: A multilevel, cross-sectional analysis of the EPOCONSUL study.

Calle Rubio M, Soriano JB, López-Campos JL, Soler-Cataluña JJ, Alcázar Navarrete B, Rodríguez González-Moro JM, Miravitlles M, Barrecheguren M, Fuentes Ferrer ME, Hermosa JLR; EPOCONSUL Study.

PLoS One. 2019 Feb 12;14(2):e0212522. doi: 10.1371/journal.pone.0212522. eCollection 2019.

6.

Correction to: Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective.

Driessen MT, Whalen J, Buguth BS, Vallejo-Aparicio LA, Naya IP, Asukai Y, Alcázar-Navarrete B, Miravitlles M, García-Río F, Risebrough NA.

Respir Res. 2019 Jan 28;20(1):18. doi: 10.1186/s12931-019-0985-2.

7.

10 Years After EPISCAN: A New Study on the Prevalence of COPD in Spain -A Summary of the EPISCAN II Protocol.

Alfageme I, de Lucas P, Ancochea J, Miravitlles M, Soler-Cataluña JJ, García-Río F, Casanova C, Rodríguez González-Moro JM, Cosío BG, Sánchez G, Soriano JB.

Arch Bronconeumol. 2019 Jan;55(1):38-47. doi: 10.1016/j.arbres.2018.05.011. Epub 2018 Jul 7. English, Spanish.

8.

Evaluating the impact of morning symptoms in COPD using the Capacity of Daily Living during the Morning (CDLM) questionnaire.

Núñez A, Esquinas C, Barrecheguren M, Calle M, Casamor R, Miravitlles M.

Int J Chron Obstruct Pulmon Dis. 2018 Nov 26;13:3837-3844. doi: 10.2147/COPD.S179402. eCollection 2018.

9.

Validation of clinical control in COPD as a new tool for optimizing treatment.

Soler-Cataluña JJ, Marzo M, Catalán P, Miralles C, Alcazar B, Miravitlles M.

Int J Chron Obstruct Pulmon Dis. 2018 Nov 14;13:3719-3731. doi: 10.2147/COPD.S178149. eCollection 2018.

10.

Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective.

Driessen MT, Whalen J, Seewoodharry Buguth B, Vallejo-Aparicio LA, Naya IP, Asukai Y, Alcázar-Navarrete B, Miravitlles M, García-Río F, Risebrough NA.

Respir Res. 2018 Nov 20;19(1):224. doi: 10.1186/s12931-018-0916-7. Erratum in: Respir Res. 2019 Jan 28;20(1):18.

11.

How whole-body vibration can help our COPD patients. Physiological changes at different vibration frequencies.

Pleguezuelos E, Casarramona P, Guirao L, Samitier B, Ortega P, Vila X, Carmen AD, Ovejero L, Moreno E, Serra N, Gomís M, Garnacho-Castaño MV, Miravitlles M.

Int J Chron Obstruct Pulmon Dis. 2018 Oct 18;13:3373-3380. doi: 10.2147/COPD.S165058. eCollection 2018.

12.

Geographical Distribution of COPD Prevalence in the Americas.

Blanco I, Diego I, Bueno P, Fernández E, Casas-Maldonado F, Esquinas C, Soriano JB, Miravitlles M.

COPD. 2018 Jun-Aug;15(4):317-325. doi: 10.1080/15412555.2018.1481936. Epub 2018 Oct 30.

PMID:
30375898
13.

Real-world effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UK.

Voorham J, Roche N, Benhaddi H, van der Tol M, Carter V, van Boven JFM, Bjermer L, Miravitlles M, Price DB.

BMJ Open. 2018 Oct 27;8(10):e022051. doi: 10.1136/bmjopen-2018-022051. Erratum in: BMJ Open. 2018 Dec 9;8(12):e022051corr1.

14.

Rebuttal From Drs Barrecheguren and Miravitlles.

Barrecheguren M, Miravitlles M.

Chest. 2018 Oct;154(4):752-753. doi: 10.1016/j.chest.2018.06.021. No abstract available.

PMID:
30290928
15.

COUNTERPOINT: Should LAMA/LABA Combination Therapy Be Used as Initial Maintenance Treatment for COPD? No.

Barrecheguren M, Miravitlles M.

Chest. 2018 Oct;154(4):749-751. doi: 10.1016/j.chest.2018.06.024. No abstract available.

PMID:
30290926
16.

Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFT® trial.

Tashkin DP, Miravitlles M, Celli BR, Metzdorf N, Mueller A, Halpin DMG, Anzueto A.

Respir Res. 2018 Oct 5;19(1):196. doi: 10.1186/s12931-018-0874-0.

17.

Population-based study of LAMA monotherapy effectiveness compared with LABA/LAMA as initial treatment for COPD in primary care.

Barrecheguren M, Monteagudo M, Miravitlles M.

NPJ Prim Care Respir Med. 2018 Sep 28;28(1):36. doi: 10.1038/s41533-018-0102-x.

18.

Ischiocrural Strength May Be a Better Prognostic Marker Than Quadriceps Strength in COPD.

Pleguezuelos E, Guirao L, Moreno E, Samitier B, Ortega P, Vila X, Garnacho-Castaño MV, Majó M, Ovejero L, Miravitlles M.

Lung. 2018 Dec;196(6):665-668. doi: 10.1007/s00408-018-0164-0. Epub 2018 Sep 21.

PMID:
30242510
19.

Recommendations on non-Pharmacological Treatment in Chronic Obstructive Pulmonary Disease From the Spanish COPD Guidelines (GesEPOC 2017).

Pleguezuelos E, Gimeno-Santos E, Hernández C, Mata MDC, Palacios L, Piñera P, Molina J, Chiner E, Miravitlles M.

Arch Bronconeumol. 2018 Nov;54(11):568-575. doi: 10.1016/j.arbres.2018.06.001. Epub 2018 Sep 18. English, Spanish.

20.

Prevalence of smoking in a psychiatric hospital and its relationship with respiratory symptoms and the prevalence of COPD.

Lores L, Monje A, Bergada M, Arellano E, Rodríguez-Larrea J, Miravitlles M.

Int J Chron Obstruct Pulmon Dis. 2018 Sep 7;13:2797-2804. doi: 10.2147/COPD.S165880. eCollection 2018.

21.

What have we learned from observational studies and clinical trials of mild to moderate COPD?

Barrecheguren M, González C, Miravitlles M.

Respir Res. 2018 Sep 17;19(1):177. doi: 10.1186/s12931-018-0882-0. Review.

22.

Real world evaluation of a novel lateral flow assay (AlphaKit® QuickScreen) for the detection of alpha-1-antitrypsin deficiency.

Greulich T, Rodríguez-Frias F, Belmonte I, Klemmer A, Vogelmeier CF, Miravitlles M.

Respir Res. 2018 Aug 13;19(1):151. doi: 10.1186/s12931-018-0826-8.

23.

What We Talk about When We Talk about Exacerbations of Chronic Obstructive Pulmonary Disease.

Miravitlles M.

Am J Respir Crit Care Med. 2019 Jan 1;199(1):2-4. doi: 10.1164/rccm.201807-1299ED. No abstract available.

PMID:
30092146
24.

The overlap between bronchiectasis and chronic airway diseases: state of the art and future directions.

Polverino E, Dimakou K, Hurst J, Martinez-Garcia MA, Miravitlles M, Paggiaro P, Shteinberg M, Aliberti S, Chalmers JD.

Eur Respir J. 2018 Sep 15;52(3). pii: 1800328. doi: 10.1183/13993003.00328-2018. Print 2018 Sep. Review.

PMID:
30049739
25.

Alpha-1 antitrypsin deficiency: outstanding questions and future directions.

Torres-Durán M, Lopez-Campos JL, Barrecheguren M, Miravitlles M, Martinez-Delgado B, Castillo S, Escribano A, Baloira A, Navarro-Garcia MM, Pellicer D, Bañuls L, Magallón M, Casas F, Dasí F.

Orphanet J Rare Dis. 2018 Jul 11;13(1):114. doi: 10.1186/s13023-018-0856-9. Review.

26.

Testing for alpha-1 antitrypsin in COPD in outpatient respiratory clinics in Spain: A multilevel, cross-sectional analysis of the EPOCONSUL study.

Calle Rubio M, Soriano JB, López-Campos JL, Soler-Cataluña JJ, Alcázar Navarrete B, Rodríguez González-Moro JM, Miravitlles M, Barrecheguren M, Fuentes Ferrer ME, Rodriguez Hermosa JL; EPOCONSUL Study.

PLoS One. 2018 Jun 28;13(6):e0198777. doi: 10.1371/journal.pone.0198777. eCollection 2018. Erratum in: PLoS One. 2019 Feb 12;14(2):e0212522.

27.

Optimal Bronchodilation for COPD Patients: Are All Long-Acting β₂-Agonist/Long-Acting Muscarinic Antagonists the Same?

Miravitlles M, Baek S, Vithlani V, Lad R.

Tuberc Respir Dis (Seoul). 2018 Jul;81(3):198-215. doi: 10.4046/trd.2018.0040. Epub 2018 Jun 19. Review.

28.

Diagnosis of alpha1-antitrypsin deficiency not just in severe COPD.

Nuñez A, Barrecheguren M, Rodríguez E, Miravitlles M, Esquinas C.

Pulmonology. 2018 Nov - Dec;24(6):351-353. doi: 10.1016/j.pulmoe.2018.05.005. Epub 2018 Jun 18.

29.

Trends of testing for and diagnosis of α1-antitrypsin deficiency in the UK: more testing is needed.

Soriano JB, Lucas SJ, Jones R, Miravitlles M, Carter V, Small I, Price D, Mahadeva R; Respiratory Effectiveness Group.

Eur Respir J. 2018 Jul 4;52(1). pii: 1800360. doi: 10.1183/13993003.00360-2018. Print 2018 Jul.

PMID:
29853490
30.

Characteristics of COPD Patients Managed in Respiratory Medicine Departments in Spain, According to GOLD Groups and GesEPOC Clinical Phenotypes.

Izquierdo JL, Miravitlles M, Esquinas C, Pérez M, Calle M, López Campos JL, Rodríguez González-Moro JM, Casanova C, Esteban C, de Lucas P.

Arch Bronconeumol. 2018 Nov;54(11):559-567. doi: 10.1016/j.arbres.2018.03.021. Epub 2018 May 28. English, Spanish.

31.

Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study.

Casas A, Montes de Oca M, Menezes AM, Wehrmeister FC, Lopez Varela MV, Mendoza L, Ramírez L, Miravitlles M.

Int J Chron Obstruct Pulmon Dis. 2018 May 11;13:1545-1556. doi: 10.2147/COPD.S154097. eCollection 2018. Erratum in: Int J Chron Obstruct Pulmon Dis. 2019 Jan 18;14:241.

32.

Chronic Obstructive Pulmonary Disease Exacerbations: A Need for Action.

Anzueto A, Miravitlles M.

Am J Med. 2018 Sep;131(9S):15-22. doi: 10.1016/j.amjmed.2018.05.003. Epub 2018 May 17.

PMID:
29777660
33.

Diagnosis of asthma-COPD overlap: Is it possible a global definition?

Miravitlles M.

Pulmonology. 2018 May - Jun;24(3):143-145. doi: 10.1016/j.pulmoe.2018.02.002. No abstract available.

34.

Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study.

Vogelmeier CF, Chapman KR, Miravitlles M, Roche N, Vestbo J, Thach C, Banerji D, Fogel R, Patalano F, Olsson P, Kostikas K, Wedzicha JA.

Int J Chron Obstruct Pulmon Dis. 2018 Apr 10;13:1125-1134. doi: 10.2147/COPD.S160011. eCollection 2018.

35.

Patient-reported Outcomes for the Detection, Quantification, and Evaluation of Chronic Obstructive Pulmonary Disease Exacerbations.

Mackay AJ, Kostikas K, Murray L, Martinez FJ, Miravitlles M, Donaldson G, Banerji D, Patalano F, Wedzicha JA.

Am J Respir Crit Care Med. 2018 Sep 15;198(6):730-738. doi: 10.1164/rccm.201712-2482CI.

36.

Are There Differences Between the Available Treatments for Emphysema Associated with Alpha-1 Antitrypsin Deficiency?

Esquinas C, Miravitlles M.

Arch Bronconeumol. 2018 Sep;54(9):451-452. doi: 10.1016/j.arbres.2018.01.006. Epub 2018 Apr 4. English, Spanish. No abstract available.

37.

Correction: Clinical and inflammatory characteristics of Asthma-COPD overlap in workers with occupational asthma.

Ojanguren I, Moullec G, Hobeika J, Miravitlles M, Lemiere C.

PLoS One. 2018 Apr 4;13(4):e0195648. doi: 10.1371/journal.pone.0195648. eCollection 2018.

38.

Long-term evolution of lung function in individuals with alpha-1 antitrypsin deficiency from the Spanish registry (REDAAT).

Esquinas C, Serreri S, Barrecheguren M, Rodriguez E, Nuñez A, Casas-Maldonado F, Blanco I, Pirina P, Lara B, Miravitlles M.

Int J Chron Obstruct Pulmon Dis. 2018 Mar 23;13:1001-1007. doi: 10.2147/COPD.S155226. eCollection 2018.

39.

Depressive status explains a significant amount of the variance in COPD assessment test (CAT) scores.

Miravitlles M, Molina J, Quintano JA, Campuzano A, Pérez J, Roncero C; DEPREPOC study investigators.

Int J Chron Obstruct Pulmon Dis. 2018 Mar 6;13:823-831. doi: 10.2147/COPD.S154791. eCollection 2018.

40.

Augmentation therapy for emphysema due to alpha-1 antitrypsin deficiency: Pro.

Barrecheguren M, Miravitlles M.

Arch Bronconeumol. 2018 Mar 16. pii: S0300-2896(18)30056-5. doi: 10.1016/j.arbres.2018.02.002. [Epub ahead of print] English, Spanish. No abstract available.

41.

Considerations for the Correct Diagnosis of COPD and Its Management With Bronchodilators.

Anzueto A, Miravitlles M.

Chest. 2018 Aug;154(2):242-248. doi: 10.1016/j.chest.2018.02.023. Epub 2018 Mar 8.

42.

New era for European Respiratory Society clinical practice guidelines: joining efficiency and high methodological standards.

Miravitlles M, Tonia T, Rigau D, Roche N, Genton C, Vaccaro V, Welte T, Gaga M, Brusselle G.

Eur Respir J. 2018 Mar 8;51(3). pii: 1800221. doi: 10.1183/13993003.00221-2018. Print 2018 Mar. No abstract available.

PMID:
29519905
43.

Evaluation of criteria for clinical control in a prospective, international, multicenter study of patients with COPD.

Miravitlles M, Sliwinski P, Rhee CK, Costello RW, Carter V, Tan J, Lapperre TS, Alcazar B, Gouder C, Esquinas C, García-Rivero JL, Kemppinen A, Tee A, Roman-Rodríguez M, Soler-Cataluña JJ, Price DB.

Respir Med. 2018 Mar;136:8-14. doi: 10.1016/j.rmed.2018.01.019. Epub 2018 Jan 31.

PMID:
29501251
44.

Clinical and inflammatory characteristics of Asthma-COPD overlap in workers with occupational asthma.

Ojanguren I, Moullec G, Hobeika J, Miravitlles M, Lemiere C.

PLoS One. 2018 Mar 2;13(3):e0193144. doi: 10.1371/journal.pone.0193144. eCollection 2018. Erratum in: PLoS One. 2018 Apr 4;13(4):e0195648.

45.

Large-scale external validation and comparison of prognostic models: an application to chronic obstructive pulmonary disease.

Guerra B, Haile SR, Lamprecht B, Ramírez AS, Martinez-Camblor P, Kaiser B, Alfageme I, Almagro P, Casanova C, Esteban-González C, Soler-Cataluña JJ, de-Torres JP, Miravitlles M, Celli BR, Marin JM, Ter Riet G, Sobradillo P, Lange P, Garcia-Aymerich J, Antó JM, Turner AM, Han MK, Langhammer A, Leivseth L, Bakke P, Johannessen A, Oga T, Cosio B, Ancochea-Bermúdez J, Echazarreta A, Roche N, Burgel PR, Sin DD, Soriano JB, Puhan MA; 3CIA collaboration.

BMC Med. 2018 Mar 2;16(1):33. doi: 10.1186/s12916-018-1013-y.

46.

Mixed Th2 and non-Th2 inflammatory pattern in the asthma-COPD overlap: a network approach.

de Llano LP, Cosío BG, Iglesias A, de Las Cuevas N, Soler-Cataluña JJ, Izquierdo JL, López-Campos JL, Calero C, Plaza V, Miravitlles M, Torrego A, Martinez-Moragon E, Soriano JB, Viña AL, Bobolea I.

Int J Chron Obstruct Pulmon Dis. 2018 Feb 12;13:591-601. doi: 10.2147/COPD.S153694. eCollection 2018.

47.

Prevalence and impact of respiratory symptoms in a population of patients with COPD in Latin America: The LASSYC observational study.

Miravitlles M, Menezes A, López Varela MV, Casas A, Ugalde L, Ramirez-Venegas A, Mendoza L, López A, Wehrmeister FC, Surmont F, Montes de Oca M.

Respir Med. 2018 Jan;134:62-69. doi: 10.1016/j.rmed.2017.11.018. Epub 2017 Nov 28.

PMID:
29413510
48.

Russian guidelines for the management of COPD: algorithm of pharmacologic treatment.

Aisanov Z, Avdeev S, Arkhipov V, Belevskiy A, Chuchalin A, Leshchenko I, Ovcharenko S, Shmelev E, Miravitlles M.

Int J Chron Obstruct Pulmon Dis. 2018 Jan 8;13:183-187. doi: 10.2147/COPD.S153770. eCollection 2018. Erratum in: Int J Chron Obstruct Pulmon Dis. 2019 Jan 18;14:243.

49.

Medical Care According to Risk Level and Adaptation to Spanish COPD Guidelines (Gesepoc): The Epoconsul Study.

Calle Rubio M, Rodríguez Hermosa JL, Soler-Cataluña JJ, López-Campos JL, Alcazar Navarrete B, Soriano JB, Rodríguez Gónzalez-Moro JM, Fuentes Ferrer ME, Miravitlles M; y el Grupo Epoconsul.

Arch Bronconeumol. 2018 May;54(5):270-279. doi: 10.1016/j.arbres.2017.11.015. Epub 2018 Feb 1. English, Spanish.

50.

Chronic obstructive pulmonary disease guidelines in Europe: a look into the future.

Miravitlles M, Roche N, Cardoso J, Halpin D, Aisanov Z, Kankaanranta H, Kobližek V, Śliwiński P, Bjermer L, Tamm M, Blasi F, Vogelmeier CF.

Respir Res. 2018 Jan 18;19(1):11. doi: 10.1186/s12931-018-0715-1. Review.

Supplemental Content

Loading ...
Support Center